Feed / INCY

Incyte Corporation

INCY

Healthcare · 129.73 +1.4% today

Isolated · not yet confirmedMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

Incyte Corporation's current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 16 directly disclosed connections are confirming.

What changed
  • Revenue increased 20.9% versus the comparable filing period.
Company+1.4% todayVolume comparison unavailable
Market group0 of 9 activeBiotechnology · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Paid demand rose 9% (three months) and 8% (six months) ended June 30, 2026 across indications; monitor future reported year‑over‑year paid demand percentages.

Invalidation: The isolated read changes if INCY's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind INCY

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

SNDXSyndax Pharmaceuticals, Inc.partnerApr 28, 2026

In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics,…

MGNXFiling-linked namepartnerApr 28, 2026

In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics,…

Depended on by

SNDXSyndax Pharmaceuticals, Inc.partnerApr 30, 2026

We are leading the commercialization and further development of revumenib and working closely with our collaboration partner, Incyte, on the commercialization and further development of axatilimab.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 20 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

INCY is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.